At the same time, neoplastic plasma cells lose the CD19, CD20, and CD22 markers in about 85% of the patients with MM [14, 15, 19] and there is little or no expression of CD45 in about 90% of the cases [20]. This evidence concerns the gene PTPRC and Miyoshi myopathy.